Compare CACI & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CACI | RVMD |
|---|---|---|
| Founded | 1962 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.9B | 15.2B |
| IPO Year | 1979 | 2020 |
| Metric | CACI | RVMD |
|---|---|---|
| Price | $581.19 | $97.52 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 17 |
| Target Price | ★ $616.50 | $77.47 |
| AVG Volume (30 Days) | 254.7K | ★ 2.9M |
| Earning Date | 01-21-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.06 | N/A |
| EPS | ★ 22.62 | N/A |
| Revenue | ★ $8,858,558,000.00 | N/A |
| Revenue This Year | $10.72 | N/A |
| Revenue Next Year | $6.19 | $714.50 |
| P/E Ratio | $24.88 | ★ N/A |
| Revenue Growth | ★ 12.61 | N/A |
| 52 Week Low | $318.60 | $29.17 |
| 52 Week High | $632.77 | $105.00 |
| Indicator | CACI | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 58.71 | 88.59 |
| Support Level | $553.49 | $76.28 |
| Resistance Level | $572.23 | $80.48 |
| Average True Range (ATR) | 14.86 | 4.87 |
| MACD | 3.59 | 2.13 |
| Stochastic Oscillator | 61.28 | 91.55 |
CACI International Inc is an information solutions and services provider, offering information solutions and services to its customers. The company's primary customers are agencies and departments of the U.S. government, which account for the vast majority of the firm's revenue. It provides information solutions and services supporting national security missions and government modernization for intelligence, defense, and federal civilian customers. Some of the services provided by the company are functional software development, data, and business analysis, IT operations support, naval architecture, and life cycle support intelligence among others. The company's operating segments are; Domestic operations and International operations. It derives key revenue from the Domestic segment.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.